BOD 0.00% 2.4¢ bod science limited

Ann: Successful 12 month evaluations cardiocel hu, page-4

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 5,278 Posts.
    lightbulb Created with Sketch. 29
    re: Ann: Successful 12 month evaluations card... All's quite on the BOD forum & sp but my pre-set diary alarm has just sounded as a reminder to the insert presented in April 8 Ann

    It would appear we'll be due for another spike this month with talk already of production planning before the 12 month follow up has even been completed

    "The proprietary ADAPT Tissue Engineering Process (TEP) has progressed through all pre-clinical animal trials and is now being evaluated in a Phase II Human Clinical Trial where ADAPT treated patch material is being used to repair heart deformities. The trial has completed the implantation phase with 30 patients receiving an ADAPT Cardiocel patch. Follow-up at 6 months has been completed, and 12 month follow-up will be completed by September 2010. bioMD, through its subsidiary Celxcel Pty Ltd, will commence a production plan for the Cardiocel patch during the coming year"

 
watchlist Created with Sketch. Add BOD (ASX) to my watchlist
(20min delay)
Last
2.4¢
Change
0.000(0.00%)
Mkt cap ! $4.256M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
BOD (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.